InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a report published on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Lake Street Capital initiated coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price objective on the stock.

InspireMD Price Performance

NYSE:NSPR opened at $3.70 on Friday. InspireMD has a one year low of $1.81 and a one year high of $3.70. The company has a market cap of $96.51 million, a P/E ratio of -4.93 and a beta of 1.00. The firm’s fifty day moving average price is $2.80 and its two-hundred day moving average price is $2.74.

Hedge Funds Weigh In On InspireMD

Several institutional investors and hedge funds have recently modified their holdings of NSPR. Parkman Healthcare Partners LLC acquired a new position in shares of InspireMD in the third quarter valued at about $279,000. Affiance Financial LLC grew its stake in shares of InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock valued at $497,000 after acquiring an additional 5,376 shares in the last quarter. Legato Capital Management LLC acquired a new position in shares of InspireMD in the fourth quarter valued at about $47,000. Essex Investment Management Co. LLC acquired a new position in shares of InspireMD in the fourth quarter valued at about $191,000. Finally, Renaissance Technologies LLC acquired a new position in shares of InspireMD in the fourth quarter valued at about $27,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.